What is KURA's current stock price?

KURA (Kura Oncology, Inc.) is currently trading at $11.01 with a market cap of $977.8M.

What sector is Kura Oncology, Inc. in?

Kura Oncology, Inc. (KURA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KURA a good stock to buy?

Analysts have a Buy consensus on KURA with a price target of $19.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KURA Kura Oncology, Inc.

Healthcare

$11.01+0.00%OpenMarket Cap: $977.8M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

9.24

P/S

13.94

EV/EBITDA

-3.30

DCF Value

$19.88

FCF Yield

-8.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

94.7%

Operating Margin

-443.5%

Net Margin

-411.2%

ROE

-142.0%

ROA

-45.1%

ROIC

-57.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$18.3M	$-73.3M	$—
Q4 null	$17.3M	$-81.0M	$—
FY null	$67.5M	$-278.7M	$—
Q3 null	$20.8M	$-74.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$19.33

Target (Median)

$20.00

Target Range

$15.00 - $23.00

2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-03-24

UBSBuy

2026-03-13

WedbushOutperform

2026-03-06

HC Wainwright & Co.Buy

2026-01-13

Leerink PartnersOutperform

2026-01-13

Trading Activity

Insider Trades

View All

Powl Brian T.officer: Chief Commercial Officer

SellFri May 22

Powl Brian T.officer: Chief Commercial Officer

SellWed May 20

FORD KATHLEENofficer: Chief Operating Officer

SellWed May 20

Bair Teresa Brophyofficer: Chief Legal Officer

SellWed May 20

WILSON TROY EDWARDdirector, officer: President and CEO

SellWed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.32

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Peers